Giant cell tumor of the tendon sheath (GCTTS) is a rare benign soft tissue tumor that is typically seen in the hand and wrist. It is an aggressive tumor that can cause significant pain and disability if not treated properly. The diagnosis of GCTTS can be challenging due to its rarity and lack of specific symptoms. This article will discuss the diagnosis and treatment of GCTTS, as well as the importance of early diagnosis and treatment.
GCTTS is a benign soft tissue tumor that is typically found in the hand and wrist. It is a rare condition, with an estimated incidence of 1.5 per 100,000 people. The tumor is composed of a mixture of fibroblasts, histiocytes, and multinucleated giant cells. It is typically located near the tendon sheath, but can also be found in other locations such as the fingers, palm, and forearm. The tumor can grow rapidly and cause significant pain and disability if not treated properly.
GCTTS typically presents with pain and swelling in the affected area. The pain may be localized or may radiate to other parts of the body. Other symptoms may include stiffness, numbness, tingling, and weakness. The tumor may cause a visible lump in the affected area.
The diagnosis of GCTTS is typically made based on the clinical presentation and imaging studies. Magnetic resonance imaging (MRI) is the most commonly used imaging modality for diagnosing GCTTS. It can be used to identify the tumor and its location, as well as any associated soft tissue changes. X-rays and ultrasound may also be used to confirm the diagnosis.
The treatment of GCTTS depends on the size and location of the tumor. Surgery is the most commonly used treatment for GCTTS. The goal of surgery is to remove the tumor and any associated tissue. If the tumor is small, it may be possible to remove it without damaging the surrounding tissue. If the tumor is large or located in an area that is difficult to access, it may be necessary to remove part of the tendon sheath or adjacent bone. Radiotherapy may also be used to treat GCTTS, either alone or in combination with surgery. Radiotherapy can be used to shrink the tumor and reduce the risk of recurrence. In some cases, chemotherapy may be used to treat GCTTS.
GCTTS is an aggressive tumor that can cause significant pain and disability if not treated properly. Early diagnosis and treatment is essential for successful management of GCTTS. Prompt diagnosis and treatment can help to reduce the risk of recurrence and improve the long-term outcome.
Giant cell tumor of the tendon sheath is a rare benign soft tissue tumor that is typically found in the hand and wrist. It can cause significant pain and disability if not treated properly. The diagnosis of GCTTS can be challenging due to its rarity and lack of specific symptoms. Early diagnosis and treatment is essential for successful management of GCTTS. Surgery is the most commonly used treatment for GCTTS, and radiotherapy and chemotherapy may also be used. It is important for doctors to be aware of the diagnosis and treatment of GCTTS in order to ensure the best possible outcome for their patients.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation